Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct;2(4):399-408.
doi: 10.2217/hep.15.32.

Intermediate hepatocellular carcinoma: the role of transarterial therapy

Fabrizio Chegai  1 , Antonio Orlacchio  2 , Stefano Merolla  2 , Serena Monti  3 , Lorenzo Mannelli  4
Affiliations

Intermediate hepatocellular carcinoma: the role of transarterial therapy

Fabrizio Chegai et al. Hepat Oncol. 2015 Oct.

Abstract

According to Barcelona Clinic Liver Cancer, the recommended first-line treatment for patients with intermediate stage of hepatocellular carcinoma (HCC) is transarterial chemoembolization. Patients with intermediate stage of HCC represent 20% with a 2-year survival of approximately 50%. Nowadays, transarterial therapies have proved precious in the treatment of hepatic malignancies. During the last years, there were important developments in practiced transarterial therapies and their efficacy is still controversial. The purpose of this review is to discuss in further details these transarterial therapies that have been used to treat cases of HCC.

Keywords: DEB TACE; chemoembolization; embolization; hepatocellular carcinoma; interventional treatment; radioembolization; transarterial chemo-occlusion; transarterial therapy.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

This manuscript was supported by Memorial Sloan Kettering Cancer Center under the institutional NIH grant: P30 CA008748. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

    1. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012;56(4):908–943. - PubMed

    2. •• Reports the standardized guidelines for the hepatocellular carcinoma (HCC) treatment.

    1. Kim WR, Gores GJ, Benson JT, Therneau TM, Melton LJ. Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology. 2005;129(2):486–493. - PubMed
    1. Tsochatzis E, Meyer T, O'Beirne J, Burroughs AK. Transarterial chemoembolisation is not superior to embolisation alone: the recent European Association for the Study of the Liver (EASL) – European Organisation for Research and Treatment of Cancer (EORTC) guidelines. Eur. J. Cancer. 2013;49(6):1509–1510. - PubMed
    1. Raoul J-L, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat. Rev. 2011;37(3):212–220. - PubMed
    1. Lewandowski RJ, Geschwind J-F, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology. 2011;259(3):641–657. - PMC - PubMed

LinkOut - more resources